WHO IS SHALIN SHAH?

Founder, CEO, and visionary behind Marius Pharmaceuticals, the company that brought Kyzatrex to market—the first FDA-approved oral testosterone replacement therapy. With a background in private equity and investing, he moved into biotech to solve a long-standing problem in hormone health: making testosterone therapy more accessible, more practical, and aligned with modern lifestyles—while supporting education, stigma reduction, and better men’s health outcomes.

In this two-part roundtable, the Biohacking Brothers sit down with Shalin Shah to break down why testosterone is a foundational longevity hormone, how Kyzatrex became the first FDA-approved oral testosterone, and what makes oral pulsatile dosing different from traditional injections.

They cover cardiovascular and cognitive implications, stigma and access, fertility concerns, SHBG and free testosterone, estrogen myths, safety markers like hematocrit, and why patient education and proper lab interpretation matter—especially in a world where testosterone levels are declining across younger men.

WHO IS SHALIN SHAH?

Founder, CEO, and visionary behind Marius Pharmaceuticals, the company that brought Kyzatrex to market—the first FDA-approved oral testosterone replacement therapy. With a background in private equity and investing, he moved into biotech to solve a long-standing problem in hormone health: making testosterone therapy more accessible, more practical, and aligned with modern lifestyles—while supporting education, stigma reduction, and better men’s health outcomes.

In this two-part roundtable, the Biohacking Brothers sit down with Shalin Shah to break down why testosterone is a foundational longevity hormone, how Kyzatrex became the first FDA-approved oral testosterone, and what makes oral pulsatile dosing different from traditional injections.

They cover cardiovascular and cognitive implications, stigma and access, fertility concerns, SHBG and free testosterone, estrogen myths, safety markers like hematocrit, and why patient education and proper lab interpretation matter—especially in a world where testosterone levels are declining across younger men.

WHO IS SANDRA KAUFAN, MD?

Dr. Sandra Kaufman is a physician and longevity scientist known for translating complex cellular aging science into practical, personalized health optimization strategies. Trained as an anesthesiologist with over two decades of clinical experience, she also has a background in cell biology—giving her a rare blend of real-world medicine and deep bench-science thinking.

She’s the author of The Kaufman Protocol: Why We Age and How to Stop It, where she introduces a structured longevity framework designed to move beyond generic “take these supplements” advice. Her work focuses on how and why cells decline over time, and how to intervene with evidence-based therapies—organized into what she calls the “Seven Tenets of Aging.” A key feature of her approach is a scoring/rating system that evaluates therapies by the strength of evidence (from theory and lab data to animal models and human outcomes), helping clinicians and patients build a longevity plan that’s more algorithmic and less guesswork.